Brook Byers (born August 2, 1945, Belleville, IL (Scott Air Force Base)) [1] is a senior partner at Kleiner Perkins Caufield & Byers and the brother of Stanford University Professor Tom Byers and Atlanta, Georgia engineering entrepreneur Ken Byers.
Brook Byers (born August 2, 1945, Belleville, IL (Scott Air Force Base)) [1] is a senior partner at Kleiner Perkins Caufield & Byers and the brother of Stanford University Professor Tom Byers and Atlanta, Georgia engineering entrepreneur Ken Byers.
Raised in Atlanta, Georgia, Byers earned a bachelor's degree in electrical engineering in 1968 from Georgia Tech and an MBA from Stanford University.
Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a top tier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. [2] [3]
Byers was the founding president and then chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is often featured on the Forbes Midas list and is currently on the board of directors of ten companies; CardioDX, Crescendo Bioscience, Inc., Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, HX Diagnostics, Pacific Biosciences, Inc., Tethys, Veracyte, Inc., and XDx, Inc. [4] Previously, he served on the board of directors of Idec Pharmaceuticals (chairman), Athena Neurosciences (chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (chairman), Hybritech (chairman), Genprobe, Nanogen, and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, personalized medicine, molecular diagnostics and genomics. [5]
Byers is currently a board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, [6] Stanford's Bio-X Advisory Council and the Stanford Eye Council. He was co-chair of the five-year, $1.4 billion, UCSF Capital Campaign. In 2007, he was awarded the "UCSF Medal" as their honorary degree equivalent. [7] In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. [8] In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association.
Byers was president and a director of the Western Association of Venture Capitalists and is a contributing author of the book Guide to Venture Capital. He is currently a board member of the University of California at San Francisco Medical Foundation, the California Healthcare Institute, the NewSchools Venture Fund, Stanford's Bio-X Advisory Council, the Stanford Eye Council and TechNet. He is co-chair of the UCSF Capital Campaign.
He was formerly a director of the Entrepreneurs Foundation, the California Healthcare Institute, the Asian Art Museum of San Francisco, the Stanford University Graduate School of Business Advisory Council, UCSF's That Man May See Vision Research Foundation (chairman), and the Georgia Tech Advisory Board, and was a founder of TechNet.
Byers is also a member of the Environmental Defense Fund. [9]
The University of California, San Francisco (UCSF), is a public land-grant research university in San Francisco, California, United States. It is part of the University of California system and is dedicated entirely to health science and life science. It conducts research and teaching in medical and biological sciences.
Kleiner Perkins, formerly Kleiner Perkins Caufield & Byers (KPCB), is an American venture capital firm which specializes in investing in incubation, early stage and growth companies. Since its founding in 1972, the firm has backed entrepreneurs in over 900 ventures, including America Online, Amazon.com, Tandem Computers, Compaq, Electronic Arts, JD.com, Square, Genentech, Google, Netscape, Sun Microsystems, Nest, Palo Alto Networks, Synack, Snap, AppDynamics, and Twitter. By 2019 it had raised around $9 billion in 19 venture capital funds and four growth funds.
Gregory Stock is an American biophysicist, best-selling author, biotechnology entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA School of Medicine. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers.
Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
CHI-California Healthcare Institute is a private, non-profit public policy research and advocacy organization, representing more than 250 universities, academic research centers, biotechnology, and medical device companies. Founded in 1993, and based in La Jolla, California, CHI has offices in Washington, D.C., and Sacramento, California. CHI publishes an annual California Biomedical Industry report, providing data on the scope and scale of academic and commercial life sciences research and development within the state. In 2008, the industry employed more than 270,000 Californians and produced revenues in excess of $75 billion.
The iFund is a US$200 million capital fund. Developers may enter into equity deals for the creation of applications, services, and components for Apple Inc.'s iPhone, iPod Touch and iPad platform. It is being offered and managed by venture capital company Kleiner, Perkins, Caufield & Byers (KPCB).
Sue Desmond-Hellmann is an American oncologist and biotechnology leader who served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. In March 2024 she was elected as a board member of OpenAI. She was previously Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position, and Arthur and Toni Rembe Rock Distinguished Professor, and before that president of product development at Genentech, where she played a role in the development of the first gene-targeted cancer drugs, Avastin and Herceptin.
Terry McGuire is a co-founder and general partner of Polaris Partners based in the Boston office. McGuire focuses on life sciences investments.
James W. Breyer is an American venture capitalist, founder and chief executive officer of Breyer Capital, an investment and venture philanthropy firm, and a former managing partner at Accel Partners, a venture capital firm. Breyer has invested in over 40 companies that have gone public or completed a merger, with some of these investments, including Facebook, earning over 100 times cost and many others over 25 times cost. On the Forbes 2021 list of the 400 richest Americans, he was ranked #389, with a net worth of US$2.9 billion.
Lindsay A. Rosenwald is an American doctor, biotechnology and life sciences industry investor. He is the co-founder of the healthcare private equity firm Opus Point Partners. Rosenwald has created and sold several biotechnological companies. In 2013 he established Fortress Biotech.
Duane J. Roth was chief executive officer and member of the board of CONNECT. He graduated from Iowa Wesleyan College.
Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information.
Michael McCullough is an American investor in healthcare and life science companies, social entrepreneur, and emergency room doctor. He was a Rhodes Scholar. He lives in Palo Alto, California.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Trevor Mervyn Jones is a visiting professor at King's College London, and a former Head of R&D, at Wellcome. He was main board director for Research & Development at The Wellcome Foundation Ltd. During his tenure, the organisation was responsible for the development of a number of significant products.
Eric Xu Yong is a Chinese entrepreneur, investor, and philanthropist. He is best known as co-founder of Baidu, the largest Chinese search engine.
William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He was a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Iambic Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
Nisa Leung is a venture capitalist and managing partner at Qiming Venture Partners. She has been named on the Forbes Midas List for six consecutive years since 2019. and ranked top 2 in Best Women Venture Capitalists by Forbes China for three successive years since 2021. She was awarded The Fortune Most Powerful Women Asia in 2024 by Fortune Asia and The Most Powerful Women in Business by Fortune China from 2022 to 2024. Nisa is widely known as China's leading investor in healthcare.